- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03826524
에피네프린 용량: 최적 대 표준 평가 시험 (EpiDOSE)
CanROC 에피네프린 용량: 최적 대 표준 평가 시험(CanROC EpiDOSE 시험)
The objective of this randomized controlled trial is to evaluate whether a low cumulative dose of epinephrine ("low dose") is non-inferior to a standard cumulative dose of epinephrine ("standard dose") with respect to survival to hospital discharge among adults undergoing resuscitation for OHCA due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT).
연구 개요
상세 설명
This study is designed as a prospective, multicentre, single-blinded randomized controlled trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.
Eligible OHCA patients will be treated by paramedics who will initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per paramedic agencies' treatment protocols. After one defibrillation and when feasible, paramedics will establish peripheral intravenous (IV) access, and patients will be randomly allocated to either the low dose or standard dose treatment arm. Epinephrine doses (according to treatment assignment) will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, until the first return of spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. Follow-up will take place using a combination of administrative databases (e.g. the Discharge Abstract Database and the National Ambulatory Care Reporting System) and telephone interviews.
This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine. Please feel free to contact epidose@unityhealth.to for further information.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Theresa Aves, MSc
- 전화번호: 46787 416-864-6060
- 이메일: theresa.aves@unityhealth.to
연구 장소
-
-
British Columbia
-
Victoria, British Columbia, 캐나다, V8W 9P1
- 모병
- British Columbia Emergency Health Services (BCEHS)
-
수석 연구원:
- Brian Grunau, MD
-
연락하다:
- Helen Connolly
- 전화번호: 604-806-8753
- 이메일: HConnolly@providencehealth.bc.ca
-
-
Ontario
-
Brampton, Ontario, 캐나다, L6T 4B9
- 모병
- Peel Regional Paramedic Services
-
수석 연구원:
- Sheldon Cheskes, MD
-
연락하다:
- Theresa Aves
- 전화번호: 46787 416-864-6060
- 이메일: theresa.aves@unityhealth.to
-
London, Ontario, 캐나다, N6E 1R4
- 모병
- Middlesex-London Paramedic Service
-
수석 연구원:
- Christian Vaillancourt, MD
-
연락하다:
- Manya Charette
- 전화번호: 17758 613-798-5555
- 이메일: mancharette@ohri.ca
-
부수사관:
- Matthew Davis, MD
-
Oakville, Ontario, 캐나다, L6M 3L1
- 모병
- Halton Region Paramedic Services
-
수석 연구원:
- Sheldon Cheskes, MD
-
연락하다:
- Theresa Aves
- 전화번호: 46787 416-864-6060
- 이메일: epidose@unityhealth.to
-
Ottawa, Ontario, 캐나다, K1H 1E2
- 모병
- Ottawa Paramedic Services
-
수석 연구원:
- Christian Vaillancourt, MD
-
연락하다:
- Manya Charette
- 전화번호: 17758 613-798-5555
- 이메일: mancharette@ohri.ca
-
Thunder Bay, Ontario, 캐나다, P7B 4X6
- 모병
- Superior North Emergency Medical Services
-
수석 연구원:
- Christian Vaillancourt, MD
-
연락하다:
- Manya Charette
- 전화번호: 17758 613-798-5555
- 이메일: mancharette@ohri.ca
-
부수사관:
- David Savage, MD
-
Waterloo, Ontario, 캐나다, N2G 4J3
- 모병
- Region of Waterloo Paramedic Services
-
연락하다:
- Kathy Winter, MD
- 전화번호: 71223 905-521-2100
- 이메일: winterkat@hhsc.ca
-
수석 연구원:
- Paul Miller, MD
-
Windsor, Ontario, 캐나다, N9A 1N6
- 모병
- Essex-Windsor Emergency Health Services
-
수석 연구원:
- Christian Vaillancourt, MD
-
연락하다:
- Manya Charette
- 전화번호: 17758 613-798-5555
- 이메일: mancharette@ohri.ca
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, 캐나다, S7J 4M2
- 모병
- Medavie Health Services West
-
연락하다:
- Tracy Wilson, PhD
- 전화번호: 306-655-2810
- 이메일: tracy.wilson@usask.ca
-
수석 연구원:
- Andrew Leach, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Out-of-hospital cardiac arrest treated by paramedics AND
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics or fire services, AND
- Established intravenous vascular access
Exclusion Criteria:
- Known or apparent age <18 years
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics
- Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
- Administration of intramuscular, endotracheal tube, or intraosseous epinephrine
- Prisoners or persons in police custody
- Known allergy or sensitivity to epinephrine
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Low Dose Epinephrine
Epinephrine up to 2mg total |
Epinephrine 1mg 1:10000 (10cc) per dose
다른 이름들:
|
|
활성 비교기: Standard Dose Epinephrine
Epinephrine up to 6mg total |
Epinephrine 1mg 1:10000 (10cc) per dose
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Survival to hospital discharge
기간: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital |
Through study completion (up to 5 years)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Return of spontaneous circulation in out-of-hospital setting
기간: Through study completion (up to 5 years)
|
Return of spontaneous circulation in the field |
Through study completion (up to 5 years)
|
|
Survival to emergency department arrival
기간: Through study completion (up to 5 years)
|
Individuals alive upon arrival to a hospital emergency department |
Through study completion (up to 5 years)
|
|
Survival to admission with death prior to discharge
기간: Through study completion (up to 5 years)
|
Individuals alive upon hospital admission who die in-hospital before being discharged |
Through study completion (up to 5 years)
|
|
Survival to discharge outside of a long-term healthcare facility e.g. nursing home
기간: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital to a care facility |
Through study completion (up to 5 years)
|
|
Modified Rankin Scale (mRS) score
기간: 12+/-3 months
|
Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead) |
12+/-3 months
|
|
Health Utility Index-3 (HUI-3) score
기간: 12+/-3 months
|
Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health) |
12+/-3 months
|
|
Hospital Anxiety and Depression Scale score
기간: 12+/-3 months
|
Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression |
12+/-3 months
|
|
Length of stay in hospital
기간: Through study completion (up to 5 years)
|
Length of time an individual remained in-hospital (length in days) |
Through study completion (up to 5 years)
|
|
Length of stay in critical care unit
기간: Through study completion (up to 5 years)
|
Length of time an individual remained in a crucial care unit (length in days) |
Through study completion (up to 5 years)
|
|
Survival post-arrest
기간: Up to 5 years
|
Survival following hospital discharge, up to 5 years |
Up to 5 years
|
|
Recurrent cardiac arrest(s)
기간: Up to 5 years
|
Number of cardiac arrests following the index arrest |
Up to 5 years
|
|
ICD implant post-arrest
기간: Up to 5 years
|
Whether an implantable cardioverter defibrillator was implanted post-arrest |
Up to 5 years
|
|
Cardiovascular re-hospitalization(s)
기간: Up to 5 years
|
Number of cardiovascular re-hospitalizations |
Up to 5 years
|
|
All-cause re-hospitalizations(s)
기간: Up to 5 years
|
Number of re-hospitalizations for any reason |
Up to 5 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Paul Dorian, MD, MSc, Unity Health Toronto
- 수석 연구원: Steve Lin, MD, MSc, Unity Health Toronto
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- EpiDOSE Protocol Version 4.0
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .